Skip to main content

Table 3 Correlation analysis of YAP1 mRNA expression levels with the clinical parameters in Indian breast cancer patients

From: Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients

Characteristic

Total (N)

YAP1 mRNA expression relative to GAPDH

p value

Normal

137

2.27 ± 1.65

0.0001

Tumor

137

0.11 ± 5.60

 

Age (years)

≤50

78 (56.93)

0.149 ± 0.00

0.464

>50

59 (43.07)

0.053 ± 0.00

 

Age at menarche

≤12

26 (18.98)

0.033 ± 0.00

0.524

>12

111 (81.02)

0.125 ± 0.00

 

Menopausal status

Premenopausal

40 (29.20)

0.036 ± 0.00

0.462

Postmenopausal

97 (70.80)

0.137 ± 0.00

 

Age at menopause

≤45

33 (34.02)

0.297 ± 1.09

0.281

>45

64 (65.98)

0.055 ± 1.98

 

ER status

Positive

81 (59.12)

0.121 ± 0.00

0.373

Negative

56 (40.88)

0.088 ± 0.00

 

PR status

Positive

47 (34.31)

0.141 ± 0.00

0.741

Negative

90 (65.69)

0.090 ± 0.00

 

Her2 status

Positive

66 (48.18)

0.053 ± 0.00

0.506

Negative

71 (51.82)

0.159 ± 0.00

 

Molecular subtypes of breast cancer

Luminal A

46 (33.58)

0.149 ± 0.00

0.731

Luminal B

38 (27.74)

0.079 ± 0.00

 

Her2-enriched

28 (20.44)

0.018 ± 0.00

 

TNBC

25 (18.25)

0.178 ± 0.00

 

Tumor size

≤5

55 (40.15)

0.183 ± 0.00

0.169

>5

82 (59.85)

0.057 ± 0.00

 

Lymph node status

Positive

99 (72.26)

0.109 ± 0.00

0.203

Negative

38 (27.74)

0.103 ± 0.00

 

Clinical stage

I+II

45(32.85)

0.206 ± 0.00

0.038

III+IV

92(67.15)

0.06 ± 0.00

 

Histological grade

I+II

95 (69.34)

0.096 ± 0.00

0.869

III

42 (30.66)

0.135 ± 0.00

 
  1. p value (Wilcoxon signed-ranked test and Kruskal-Wallis test), Bonferroni significance level p ≤ 0.004